All In Biotech

Drug Trial Radar · NCT05504278

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

An Open-label, Multi-center Phase Ib/III Study Evaluating the Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Sep 20, 2022

Primary completion

May 31, 2025

Study completion Jul 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.

Conditions

  • Advanced Non-Small Cell Lung Cancer

Interventions

  • IBI351Drug

    recommended dose, po

  • CetuximabDrug

    500mg/m\^2, Q2W, day1, i.v.

  • pemetrexedDrug

    500mg/m\^2, Q3W, day1, i.v.

  • CarboplatinDrug

    AUC=5, Q3W, day1, i.v.

  • SintilimabDrug

    200mg, Q3W, day1, i.v.

  • cis-platinumDrug

    75mg/m\^2, Q3W, day1, i.v.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicityTime frame: 12 months
  2. Evaluate clinical efficacy of IBI351 in combination with other therapeutic agentsTime frame: 24 months
  3. Safety indicators during the introduction phase for IBI351 combination treatment :Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jilin Province Cancer Hospital

    Jilin City, Changchun, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.